Search
Powered By HealthLine
Special Offers
Health Tools
 Heart Healthy Diet
 Ideal Body Weight Calculator
 Diet Reviews
 Fitness and Family
 Quiz: Test Your Fitness IQ
 Exercise and Fitness Guide
 Eat Out Smart
 Healthy Cooking
 BMI Calculator
Featured Conditions
 Diet & Exercise
 Stop Smoking
 Food & Fitness
 High Blood Pressure
 Cholesterol
 Heart
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
In-Depth Reports
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today
PR Newswire
 Read latest







Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine| Drug Checker
 Printer Friendly  Send to a Friend

Gene Variant Could Lower Alzheimer's Risk

Carrying two 'good' copies slows age-linked mental decline by half, study found

By Ed Edelson
HealthDay Reporter


Related Encyclopedia
 border=
Acoustic Neurinoma
Alzheimer's Disease
Bell's Palsy
Brain and Spinal Cord Magnetic Resonance Imaging
More...

Related Healthscout Videos
 border=
New Improved Metal Hearts
Two for One Heart Repair
Fixing Foot Drop
Stem Cells Save Legs?
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Erectile Dysfunction
What is a Heart Attack?
More...

Related Drug Information
 border=
Actonel
Adderal XR
Concerta
Coumadin
More...

Related News Articles
 border=
Doctor Shortage Adds to Pain of Juvenile Arthritis
Lifetime of Arthritis Has Not Held Back Teen
Health Tip: Why Do My Joints Hurt?
Better Methods Needed to Measure Hospital Quality: Experts
More...

TUESDAY, Jan. 12 (HealthDay News) -- A gene variant that is good for the heart also appears to be good for the brain, slowing age-related decline in mental function and cutting the odds for Alzheimer's disease, a study indicates.

"If you carry two copies of the favorable form of the gene, it reduces the risk of Alzheimer's disease by 70 percent," explained study lead author Dr. Richard B. Lipton, professor and vice chair of neurology at Albert Einstein College of Medicine in New York City.

Text Continues Below



Drugs that mimic the activity of the gene variant already are being developed, said Lipton, whose group reported the finding in the Jan. 13 issue of the Journal of the American Medical Association.

A 2003 study by Lipton and his associates identified a variant of the gene for cholesterol ester transfer protein (CETP) -- involved in carrying cholesterol in the bloodstream -- as being associated with a longer life span. "The longer you live, the more common is the favorable variant," Lipton noted. "The incidence is 5 percent at age 50 and 35 percent at age 95."

The new study followed 523 people, all age 70 or older, for four years, testing their mental function and relating it to the variant of the CETP gene they carried.

Participants who carried two copies of the variant gene experienced an age-related decline in mental function that was about half as rapid as people with two normal versions of the gene, the study found.

Individuals with two copies of the favorable CETP variant also had a reduced risk of developing Alzheimer's disease compared to those with two normal versions of the gene, the study found.

Besides its effects on the brain, the favorable CETP gene variant also appears to boost blood levels of HDL ("good") cholesterol, which helps prevent artery-blocking clots from forming.

How does the gene variant work its magic? Lipton put forth two theories.

"We know that it protects against disease in blood vessels," he said. "It lowers the risk of heart attack and stroke, and stroke is a risk factor for cognitive decline. So it protects the brain against atherosclerotic disease.

Page:  1 | 2 | Next >>

Copyright © 2010 ScoutNews, LLC. All rights reserved.
Last updated 1/12/2010

Related Links
 border=
From Healthscout's partner site on alzheimer's disease, OurAlzheimers.com
I need to know about Alzheimer's symptoms.
What are the stages of Alzheimer's Disease?
Learn about Alzheimer's medications.





SOURCES: Richard B. Lipton, M.D., professor, vice chair, neurology, Albert Einstein College of Medicine, New York City; James Burke, M.D, Ph.D., director, Memory Disorders Clinic, Duke University Medical Center, Durham, N.C; Jan. 13, 2010 Journal of the American Medical Association


HealthScout is a part of HealthCentral
About Us   Our Blog   Contact Us   Privacy Policy   Terms of Use   Site Map  
Copyright © 2001-2010. The HealthCentralNetwork, Inc. All rights reserved.
Advertising Policy   Editorial Policy Advertise With Us   Anti-Spam Policy   PR Newswire